Reuters: Regulatory News: Novo Nordisk says new data show Victoza advantage

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Novo Nordisk says new data show Victoza advantage Nov 27th 2012, 08:28 COPENHAGEN | Tue Nov 27, 2012 3:28am EST COPENHAGEN Nov 27 (Reuters) - Denmark's Novo Nordisk on Tuesday said new data showed an advantage for type two diabetes patients given its diabetes drug Victoza compared with rival drugs from Merck & Co and Amylin Pharmaceuticals Inc. The world's biggest insulin producer said in a statement that more type two diabetes patients given Victoza achieved an average blood sugar level below seven percent than those given Merck's sitagliptin (Januvia) or Amylin's exenatid BID. For non-diabetics, the usual blood sugar level is between 4 and five percent, while a level of 6.5 percent is considered good blood sugar control for people with diabetes. Improving blood sugar control can help reduce the risk of complications associated with diabetes. The study had monitored patients given Victoza (liraglutide) over 26 weeks, compared with patients given the two rival treatments, Novo Nordisk said.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions